Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease

Ole Haagen Nielsen*, Theresa Louise Boye, Deepavali Chakravarti, John Gubatan

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

14 Citations (Scopus)
10 Downloads (Pure)

Abstract

Recent significant advances have been made in the treatment of chronic inflammatory diseases with initiation of the era of biologics. However, an unmet medical need still exists for novel targeted therapies. Compared with biologics, Janus kinase inhibitors (JAKis) are a new drug class of orally administered small molecules that have been shown to efficiently modulate complex cytokine-driven inflammation in preclinical models and human studies. Unfortunately, serious adverse effects have been reported with the first introduced pan-JAKi, tofacitinib. Here, we review tyrosine kinase 2 (TYK2) signaling in the pathophysiology of inflammatory bowel disease (IBD), examine mechanisms of action of selective TYK2 inhibitors (TYK2is), and discuss the potential for these inhibitors in efforts to balance benefits and harms.

Original languageEnglish
JournalTrends in Pharmacological Sciences
Volume43
Issue number5
Pages (from-to)424-436
ISSN0165-6147
DOIs
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Ltd

Keywords

  • Crohn disease
  • Janus kinase
  • signal transducers and activators of transcription
  • small molecules
  • therapy
  • tyrosine kinase 2
  • ulcerative colitis

Cite this